Literature DB >> 20222094

A role for the pregnane X receptor in flucloxacillin-induced liver injury.

Elise Andrews1, Martin Armstrong, Jonathan Tugwood, Dan Swan, Philip Glaves, Munir Pirmohamed, Guruprasad P Aithal, Matthew C Wright, Christopher P Day, Ann K Daly.   

Abstract

UNLABELLED: Drug-induced liver injury (DILI) due to flucloxacillin is a rare but serious complication of treatment. There is some evidence that flucloxacillin is a human pregnane X receptor (PXR) agonist. This study was designed to investigate the relevance of PXR to flucloxacillin toxicity and to identify genes changing in expression in response to flucloxacillin. Changes in gene expression in human hepatocytes after treatment with 500 microM flucloxacillin for 72 hours were examined by expression microarray analysis. The ability of flucloxacillin to act as a PXR agonist was investigated with reporter gene experiments. Flucloxacillin DILI cases (n = 51), drug-exposed controls without toxicity (n = 64), and community controls (n = 90) were genotyped for three common PXR polymorphisms. Luciferase reporter assays were used to assess the significance of a promoter region PXR polymorphism. Seventy-two probe sets representing 50 different genes showed significant changes in expression of 1.2-fold or higher. Most genes showing changes greater than 3-fold were known to be rifampicin-responsive, and this suggested a PXR-dependent mode of regulation. Using a luciferase-everted repeat separated by 6 base pairs element construct, we confirmed that flucloxacillin was a PXR agonist. We found a difference in the distribution of a PXR polymorphism (rs3814055; C-25385T) between flucloxacillin DILI cases and controls with the CC genotype associated with an increased risk of disease (odds ratio = 3.37, 95% confidence interval = 1.55-7.30, P = 0.0023). Reporter gene experiments showed lower promoter activity for the C allele than the T allele.
CONCLUSION: Flucloxacillin is a PXR agonist at pharmacologically relevant concentrations, and a functionally significant upstream PXR polymorphism is a risk factor for flucloxacillin-induced DILI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20222094     DOI: 10.1002/hep.23549

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

Review 1.  Drug-induced cholestasis.

Authors:  Manmeet S Padda; Mayra Sanchez; Abbasi J Akhtar; James L Boyer
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

Review 2.  Pregnane X receptor and drug-induced liver injury.

Authors:  Yue-Ming Wang; Sergio C Chai; Christopher T Brewer; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-09-25       Impact factor: 4.481

Review 3.  Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.

Authors:  Robert J Fontana
Journal:  Gastroenterology       Date:  2013-12-31       Impact factor: 22.682

Review 4.  Mechanisms of drug-induced liver injury: from bedside to bench.

Authors:  Shannan Tujios; Robert J Fontana
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

Review 5.  Drug-induced liver injury in older adults.

Authors:  Sarah J Mitchell; Sarah N Hilmer
Journal:  Ther Adv Drug Saf       Date:  2010-12

6.  A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform.

Authors:  Y Choi; F Jiang; H An; H J Park; J H Choi; H Lee
Journal:  Pharmacogenomics J       Date:  2016-02-16       Impact factor: 3.550

Review 7.  Pharmacogenomics of adverse drug reactions.

Authors:  Ann K Daly
Journal:  Genome Med       Date:  2013-01-29       Impact factor: 11.117

Review 8.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

Review 9.  PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches.

Authors:  Jingheng Wang; Monicah Bwayi; Rebecca R Florke Gee; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-06-16       Impact factor: 4.481

Review 10.  Targeting the pregnane X receptor in liver injury.

Authors:  Tao Li; Ruth T Yu; Annette R Atkins; Michael Downes; Robert H Tukey; Ronald M Evans
Journal:  Expert Opin Ther Targets       Date:  2012-08-23       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.